BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• 

  C-suite

  Lilly, J&J CEOs top pharma’s highest paid list—again

  Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by more than $4 million.

  May 13, 2026

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  Mergers & acquisitions

  Mid-sized European drugmakers are snapping up US biotechs. Will the surge continue?

  European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.

  May 13, 2026

   · 

  4 min read

   · 

  Nick Paul Taylor
• 

  Career Advice

  Scientist as strategist: expanding the role beyond the bench

  Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.

  May 13, 2026

   · 

  5 min read

   · 

  Manali Shah
• 

  FDA

  After ‘most damaging period in FDA history,’ Makary will be hard to replace

  With Commissioner Marty Makary’s exit, the FDA will enter a period of “unprecedented” and “prolonged” leadership vacuum, analysts at Capital Alpha predicted, noting that the government will have trouble finding someone who will want to take the FDA’s reins.

  May 13, 2026

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Venture capital

  AI-fueled Isomorphic bags $2.1B, the second largest biotech round ever

  Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets.

  May 13, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Obesity

  Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching

  Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies.

  May 13, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  FDA

  Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

  It’s official: FDA Commissioner Marty Makary is out at the FDA after reports of his ouster emerged late last week; Sanofi is reportedly having challenges with one of the FDA’s new signature programs; and biopharma CEOs’ multimillion-dollar salaries ticked up again this year. Who made the most in 2025?

  May 13, 2026

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Complete response letters

  UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged

  After devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving. But analysts don’t expect much relief, no matter who helms the agency.

  May 13, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Earnings

  Goodbye Galapagos: chameleon company exits the island, rebrands as Lakefront

  After a 12-month period that saw the Belgian biotech consider a spinout, swap out CEOs, and enter a three-way acquisition agreement involving Ouro Medicines, Galapagos now has a new moniker.

  May 13, 2026

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Manufacturing

  Bora inks $122.5M takeover of MacroGenics facility to further US expansion

  MacroGenics is selling the manufacturing plant to Bora, a Taiwan-based CDMO, to raise cash to support the progress of its drug development pipeline.

  May 13, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor